Changes in physical activity in people with idiopathic pulmonary fibrosis before and after virtual pulmonary rehabilitation: a feasibility study

Autor: Orlagh O’Shea, Grainne Murphy, Lynn Fox, Katherine M.A. O’Reilly

Publikováno v: BMC Pulmonary Medicine, Vol 24, Iss 1, Pp 1-8 (2024)

Abstract Background Pulmonary rehabilitation (PR) is recommended for the treatment of people with idiopathic pulmonary fibrosis (IPF). Physical activity is an important health behaviour, closely linked to survival in people with IPF. Little is known

Externí odkaz: https://doaj.org/article/55ecc09d5d8646a78fbb6fa7ee608cd9

Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus

Autor: Murray B. Urowitz, Cynthia Aranow, Yumi Asukai, Damon L. Bass, Ian N. Bruce, Deven Chauhan, Maria Dall'Era, Richard Furie, Norma Lynn Fox, Jennifer A. Gilbride, Anne Hammer, Ellen M. Ginzler, Tania Gonzalez‐Rivera, Roger A. Levy, Joan T. Merrill, Holly Quasny, David A. Roth, William Stohl, Ronald van Vollenhoven, Daniel J. Wallace, Michelle Petri

Publikováno v: Urowitz, M B, Aranow, C, Asukai, Y, Bass, D L, Bruce, I N, Chauhan, D, Dall'Era, M, Furie, R, Fox, N L, Gilbride, J A, Hammer, A, Ginzler, E M, Gonzalez-Rivera, T, Levy, R A, Merrill, J T, Quasny, H, Roth, D A, Stohl, W, van Vollenhoven, R, Wallace, D J & Petri, M 2022, ' Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus ', Arthritis Care and Research, vol. 74, no. 11, pp. 1822-1828 . https://doi.org/10.1002/acr.24901

Organ damage is a key determinant of poor long-term prognosis and early death in patients with systemic lupus erythematosus (SLE). Prevention of damage is a key treatment goal of the 2019 update of the European Alliance of Associations for Rheumatolo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c81a899c9b46ed97a967794594c7bb5
http://www.scopus.com/inward/record.url?scp=85135523522&partnerID=8YFLogxK

Supplementary Data from Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: a Phase I Study

Autor: Stefan Sleijfer, Elisabeth G.E. de Vries, Walter J. Loos, Ferry A.L.M. Eskens, Renée Miceli, Norma Lynn Fox, Jourik A. Gietema, Corina N.A.M. Oldenhuis, Jaap Verweij, Constantijne H. Mom

Supplementary Data from Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: a Phase I Study

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6bc8175e10fc63c1c449e22f11fd3876
https://doi.org/10.1158/1078-0432.22440649

Adaptation of a Shared Decision-Making Tool for Early Rheumatoid Arthritis Treatment Decisions with Indigenous Patients

Autor: Valerie Umaefulam, Claire E.H. Barber, Glen Hazlewood, Terri-Lynn Fox, Cheryl Barnabe, Nick Bansback

Publikováno v: The Patient - Patient-Centered Outcomes Research. 15:233-243

Patient decision aids (PtDAs) enable shared decision-making between patients and healthcare providers. Adaptations to PtDAs for use with populations facing inequities in healthcare can improve the relevancy of information presented, incorporate appro

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::610a4968f98173c63773d5820ea9b8db
https://doi.org/10.1007/s40271-021-00546-8

Treating Opioid Use Disorder With a Monthly Subcutaneous Buprenorphine Depot Injection: 12-Month Safety, Tolerability, and Efficacy Analysis

Autor: Barbara R. Haight, Norma Lynn Fox, Sunita Shinde, Anne Andorn, David R. Hassman, Paul J. Fudala, Susan M Learned, Christian Heidbreder, Vijay R Nadipelli, Daniel Rutrick, Y Zhao

Publikováno v: Journal of Clinical Psychopharmacology

Supplemental digital content is available in the text.
Background BUP-XR (RBP-6000 or SUBLOCADE) is the first Food and Drug Administration–approved subcutaneously administered monthly extended-release buprenorphine medication for the treatment

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e7f24f63585d4b3e1294bd57656ffd4
https://pubmed.ncbi.nlm.nih.gov/32282418